CHEMOS
DLin-MC3-DMA

DLin-MC3-DMA

Chemical Name

[(6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yl] 4-(dimethylamino)butanoate

DLin-MC3-DMA•LNP
Structure: DLin-MC3-DMA structure, CAS 1224606-06-7, MW 642.09
Product No
CH51003
CAS
1224606-06-7
MF
C43H79NO2
MW
642.09
Specification
Catalog No.CH51003
CAS No.1224606-06-7
Molecular FormulaC43H79NO2
Molecular Weight642.09

CHEMOS Support for This Category

CHEMOS supports custom synthesis and process development for LNP lipid components, with work planned according to target structure, requested scale, and analytical requirements. Ionizable lipid route development : route scouting, impurity review, stereochemistry control, and purification planning. Helper lipid and PEG-lipid preparation : support for phospholipids, sterol-related components, PEG-lipids, and related analogs. Analytical support : HPLC, NMR, MS, Karl Fischer water content, elemental analysis, and residual-solvent testing can be discussed by project. Scale-up support : transfer from laboratory preparation to larger pilot or production batches after route and quality review. Project documentation : batch-specific COA and technical information are provided according to the confirmed specification.

Overview

DLin-MC3-DMA (also known as [(6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yl] 4-(dimethylamino)butanoate) (CAS 1224606-06-7, MF C43H79NO2, MW 642.09) is an ionizable lipid analog studied in lipid nanoparticle (LNP) formulations for nucleic acid delivery research, including mRNA and siRNA platforms. Practical chemistry topics around this compound include head-group structure, ester or amine linker chemistry, and tail unsaturation. Project scale-up and custom synthesis are coordinated by the CHEMOS R&D team across laboratory and production sites.

Applications

  • DLin-MC3-DMA (1224606-06-7) supply and analog preparation for research programs
  • Lipid nanoparticle (LNP) formulation research for mRNA / siRNA delivery
  • Ionizable lipid library and head-group / tail analog screening
  • Process-development support for scalable ionizable lipid preparation

Need Custom Synthesis?

Our CDMO team provides end-to-end custom synthesis support from discovery through process development and scale-up.

Explore CDMO Services